PMC6247720_01
Case 1: biweekly romiplostim.
CRIHEM2018-6037494.001.jpg
PMC6247720_01_CRIHEM2018-6037494.001.jpg
fig1
Due to platelet counts remaining in the 200-600 x 109/L range, she was switched to biweekly dosing of romiplostim 250 microg and was able to maintain stable platelet counts for 11 consecutive weeks (Figure 1).
PMC6247720_02
Case 2: biweekly romiplostim.
CRIHEM2018-6037494.002.jpg
PMC6247720_02_CRIHEM2018-6037494.002.jpg
fig2
The patient was able to maintain stable platelet counts for 131 consecutive weeks; however, due to a lapse in private medication coverage, the patient discontinued romiplostim altogether (Figure 2).
PMC6247720_03
Case 3: biweekly romiplostim.
CRIHEM2018-6037494.003.jpg
PMC6247720_03_CRIHEM2018-6037494.003.jpg
fig3
She maintained stable platelet counts on weekly romiplostim dosing for 94 weeks before being switched to biweekly romiplostim 75 microg therapy and was able to maintain stable platelet counts for 20 weeks (Figure 3).
Case 3: triweekly romiplostim.
CRIHEM2018-6037494.004.jpg
PMC6247720_03_CRIHEM2018-6037494.004.jpg
fig4
On q3weekly dosing, she was still able to maintain high platelet counts for 12 weeks (Figure 4), and thus, romiplostim therapy was discontinued altogether while monitoring the patient closely.